Discovery of a Selective PROTAC Degrading Untamable BCR::ABL1 Compound Mutants in Chronic Myelogenous Leukemia (CML)and Philadelphia Chromosome-Positive (Ph plus ) Acute Lymphoblastic Leukemia (ALL)

被引：0

作者：

Rouhimoghadam, Milad ^{[1
]}

Tang, Hua ^{[2
]}

Bates, Briana ^{[1
]}

Liao, Junzhuo ^{[2
]}

Uribe-Cano, Daniela

Tang, Weiping ^{[1
,2
]}

Deininger, Michael ^{[1
]}

机构：

[1] Versiti Blood Res Inst, Milwaukee, WI USA

[2] Univ Wisconsin Madison, Madison, WI USA

来源：

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2023年 / 23卷

关键词：

CML; BCR::ABL1; PROTAC; degrader; TKI;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

CML-305

引用

页码：S336 / S336

页数：1

共 50 条

[21] Discontinuation of Tyrosine Kinase Inhibitors (TKIs) in Philadelphia Chromosome-Positive (Ph plus ) Acute Lymphoblastic Leukemia (ALL)
Samra, Bachar
Kantarjian, Hagop M.
Sasaki, Koji
Konopleva, Marina Y.
Khouri, Rita
O'Brien, Susan M.
Ferrajoli, Alessandra
Nunez, Cesar
Kadia, Tapan M.
Jabbour, Elias
BLOOD, 2019, 134
[22] The ela3 BCR-ABL1 Fusion Transcript in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
Langabeer, Stephen E.
ANNALS OF LABORATORY MEDICINE, 2015, 35 (05) : 540 - 541
[23] Detection of bcr-abl transcripts in Philadelphia chromosome-positive acute lymphoblastic leukemia after marrow transplantation
Radich, J
Gehly, G
Lee, A
Avery, R
Bryant, E
Edmands, S
Gooley, T
Kessler, P
Kirk, J
Ladne, P
Thomas, ED
Appelbaum, FR
BLOOD, 1997, 89 (07) : 2602 - 2609
[24] A NOVEL VARIANT OF THE BCR-ABL FUSION PRODUCT IN PHILADELPHIA CHROMOSOME-POSITIVE ACUTE LYMPHOBLASTIC-LEUKEMIA
SOEKARMAN, D
VANDENDEREN, J
HOEFSLOOT, L
MORET, M
MEEUWSEN, T
VANBAAL, J
HAGEMEIJER, A
GROSVELD, G
LEUKEMIA, 1990, 4 (06) : 397 - 403
[25] Selective induction of apoptosis in Philadelphia chromosome-positive chronic myelogenous leukemia cells by an inhibitor of BCR–ABL tyrosine kinase, CGP 57148
Shingo Dan
Mikihiko Naito
Takashi Tsuruo
Cell Death & Differentiation, 1998, 5 : 710 - 715
[26] Novel Abl kinase inhibitors in chronic myeloid leukemia in blastic phase and Philadelphia chromosome-positive acute lymphoblastic leukemia
Swords, Ronan
Alvarado, Yesid
Giles, Francis
CLINICAL LYMPHOMA & MYELOMA, 2007, 7 : S113 - S119
[27] Results of imatinib mesylate (STI571), a bcr-abl tyrosine kinase inhibitor, in Philadelphia chromosome-positive chronic myelogenous leukemia in blastic phase (Ph plus CML BP).
Kantarjian, HM
Cortes, J
O'Brien, S
Giles, F
Albitar, M
Rios, MB
Shan, J
Faderl, S
Garcia-Manero, G
Issa, JP
Thomas, D
Capdeville, R
Talpaz, M
BLOOD, 2001, 98 (11) : 260B - 260B
[28] A novel BCR-ABL1 mutation in a patient with Philadelphia chromosome-positive B-cell acute lymphoblastic leukemia
Vinhas, Raquel
Lourenco, Alexandra
Santos, Susana
Lemos, Marcos
Ribeiro, Patricia
de Sousa, Aida Botelho
Baptista, Pedro Viana
Fernandes, Alexandra Ramos
ONCOTARGETS AND THERAPY, 2018, 11 : 8589 - 8598
[29] Dynamic Prediction of Outcome with Longitudinal BCR-ABL1 Levels in Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
Sasaki, Koji
Kantarjian, Hagop
Richard-Carpentier, Guillaume
Ravandi, Farhad
Short, Nicholas
Garcia-Manero, Guillermo
Daver, Naval
Kadia, Tapan
Konopleva, Marina
Jain, Nitin
Issa, Ghayas
Jeanis, Vicki
Alvarez, Joie
Khouri, Maria
Nasnas, Patrice
Garris, Rebecca
Wierda, William
Thompson, Philip
Pemmaraju, Naveen
Cortes, Jorge
O'Brien, Susan
Jabbour, Elias
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 : S180 - S181
[30] ABL1-BCR MRNA EXPRESSION IN CHRONIC MYELOID LEUKEMIA AND PHILADELPHIA POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA
Mori, Sayaka
Hasegawa, Hiroo
Sasaki, Daisuke
Tsuruda, Kazuto
Miyazaki, Yasushi
Yanagihara, Katsunori
INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY, 2016, 38 : 76 - 76

← 1 2 3 4 5 →